145 related articles for article (PubMed ID: 17938796)
1. The influence on INRs and coagulation factors of the time span between blood sample collection and intake of phenprocoumon or acenocoumarol: consequences for the assessment of the dose.
van Geest-Daalderop JH; Hutten BA; Péquériaux NC; Haas FJ; Levi M; Sturk A
Thromb Haemost; 2007 Oct; 98(4):738-46. PubMed ID: 17938796
[TBL] [Abstract][Full Text] [Related]
2. Invasive procedures in the outpatient setting: managing the short-acting acenocoumarol and the long-acting phenprocoumon.
van Geest-Daalderop JH; Hutten BA; Péquériaux NC; de Vries-Goldschmeding HJ; Räkers E; Levi M
Thromb Haemost; 2007 Oct; 98(4):747-55. PubMed ID: 17938797
[TBL] [Abstract][Full Text] [Related]
3. [Switching from acenocoumarol to phenprocoumon: step in personalised anticoagulation?].
van Miert JHA; Piersma-Wichers M; Meijer K
Ned Tijdschr Geneeskd; 2021 Sep; 165():. PubMed ID: 34523845
[TBL] [Abstract][Full Text] [Related]
4. Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: A cohort study.
van Miert JHA; Veeger NJGM; Ten Cate-Hoek AJ; Piersma-Wichers M; Meijer K
PLoS One; 2020; 15(7):e0235639. PubMed ID: 32649714
[TBL] [Abstract][Full Text] [Related]
5. Variability of INR in patients on stable long-term treatment with phenprocoumon and acenocoumarol and implications for analytical quality requirements.
van Geest-Daalderop JH; Péquériaux NC; van den Besselaar AM
Thromb Haemost; 2009 Sep; 102(3):588-92. PubMed ID: 19718481
[TBL] [Abstract][Full Text] [Related]
6. Point-of-care testing and INR within-subject variation in patients receiving a constant dose of vitamin K antagonist.
van den Besselaar AM; Biedermann JS; Kruip MJ
Thromb Haemost; 2015 Nov; 114(6):1260-7. PubMed ID: 26202616
[TBL] [Abstract][Full Text] [Related]
7. Statin use decreases coagulation in users of vitamin K antagonists.
van Rein N; Biedermann JS; Bonafacio SM; Kruip MJ; van der Meer FJ; Lijfering WM
Eur J Clin Pharmacol; 2016 Dec; 72(12):1441-1447. PubMed ID: 27709253
[TBL] [Abstract][Full Text] [Related]
8. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time.
Harder S; Graff J; Klinkhardt U; von Hentig N; Walenga JM; Watanabe H; Osakabe M; Breddin HK
Thromb Haemost; 2004 Jun; 91(6):1137-45. PubMed ID: 15175800
[TBL] [Abstract][Full Text] [Related]
9. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing.
Walenga JM; Drenth AF; Mayuga M; Hoppensteadt DA; Prechel M; Harder S; Watanabe H; Osakabe M; Breddin HK
Clin Appl Thromb Hemost; 2008 Jul; 14(3):325-31. PubMed ID: 18586683
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon.
Gadisseur AP; van der Meer FJ; Adriaansen HJ; Fihn SD; Rosendaal FR
Br J Haematol; 2002 Jun; 117(4):940-6. PubMed ID: 12060134
[TBL] [Abstract][Full Text] [Related]
11. Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants.
Visser LE; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH
Pharmacogenet Genomics; 2005 Feb; 15(2):69-74. PubMed ID: 15861030
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort.
Maagdenberg H; Bierings MB; van Ommen CH; van der Meer FJM; Appel IM; Tamminga RYJ; de Boer A; Maitland-van der Zee AH
J Thromb Haemost; 2018 Jan; 16(1):116-124. PubMed ID: 29108090
[TBL] [Abstract][Full Text] [Related]
13. Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands.
Zhang Y; de Boer A; Verhoef TI; van der Meer FJ; Le Cessie S; Maitland-van der Zee AH; ;
Thromb Res; 2015 Jul; 136(1):94-100. PubMed ID: 25971661
[TBL] [Abstract][Full Text] [Related]
14. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon.
Fihn SD; Gadisseur AA; Pasterkamp E; van der Meer FJ; Breukink-Engbers WG; Geven-Boere LM; van Meegen E; de Vries-Goldschmeding H; Antheunissen-Anneveld I; van't Hoff AR; Harderman D; Smink M; Rosendaal FR
Thromb Haemost; 2003 Aug; 90(2):260-6. PubMed ID: 12888873
[TBL] [Abstract][Full Text] [Related]
15. Interaction of OTC drug noscapine and acenocoumarol and phenprocoumon.
Lokhorst B; Rolfes L; Jessurun NT
Br J Clin Pharmacol; 2019 May; 85(5):1041-1043. PubMed ID: 30809820
[No Abstract] [Full Text] [Related]
16. The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants.
Visser LE; Bleumink GS; Trienekens PH; Vulto AG; Hofman A; Stricker BH
Br J Haematol; 2004 Oct; 127(1):85-9. PubMed ID: 15384981
[TBL] [Abstract][Full Text] [Related]
17. Subtherapeutic oral anticoagulant therapy: frequency and risk factors.
Rombouts EK; Rosendaal FR; van der Meer FJ
Thromb Haemost; 2009 Mar; 101(3):552-6. PubMed ID: 19277419
[TBL] [Abstract][Full Text] [Related]
18. Quality control of oral anticoagulation with vitamin K antagonists in primary care patients in Poland: a multi-centre study.
Sawicka-Powierza J; Buczkowski K; Chlabicz S; Gugnowski Z; Powierza K; Ołtarzewska AM
Kardiol Pol; 2018; 76(4):764-769. PubMed ID: 29313558
[TBL] [Abstract][Full Text] [Related]
19. Opposite effects of lornoxicam co-administration on phenprocoumon pharmacokinetics and pharmacodynamics.
Masche UP; Rentsch KM; von Felten A; Meier PJ; Fattinger KE
Eur J Clin Pharmacol; 1999 Jan; 54(11):857-64. PubMed ID: 10027661
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
Ufer M
Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
